|
|||||
|
|
Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease |
|
| Authors: | N. Vande Casteele B. G. Feagan S. Vermeire M. Yassine J. Coarse G. Kosutic W. J. Sandborn |
| Affiliation: | 1. Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA;2. Robarts Clinical Trials, Western University, London, ON, Canada;3. Translational Research in GastroIntestinal Disorders (TARGID), KU Leuven, Leuven, Belgium;4. UCB Pharma, Smyrna, GA, USA;5. UCB Pharma, Raleigh, NC, USA |
| Abstract: | |
| Keywords: | |